Sep 17, 2021 / 02:00PM GMT
Steven L. Hoerter - Deciphera Pharmaceuticals, Inc. - President, CEO & Director
Good morning and thank you for joining us for today's webcast to discuss 2 important clinical updates from this year's European Society of Medical Oncology congress. At this year's congress, we're excited to present updated clinical data from the vimseltinib and rebastinib programs, which support our plans to initiate a Phase III pivotal study for vimseltinib in the fourth quarter of this year and to initiate a Phase III study for rebastinib in 2022, pending regulatory feedback.
As you know, we'll be making certain forward-looking statements during the course of the event this morning, and I would ask that you refer the set of risk factors shown on this slide and available on our SEC filings, which you can find at deciphera.com.
During the course of this year, we've made tremendous progress on our strategic priorities across our portfolio of best-in-class and first-in-class product candidates. Building on the successful launch of QINLOCK in fourth-line GIST in the United States, we expect approval for the
Deciphera Pharmaceuticals Inc Virtual Investor Event to Discuss Rebastinib and Vimseltinib Data Presented at ESMO Transcript
Sep 17, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers